Yep 1300 on the cards again |
Every chart for this horrific, prob a buy to trade again around 12.80, rinse and repeat. U.K. shares known as “ the bug zapper trade “ for a reason. |
 Two stocks to buy in a cheap sector
There are a couple of companies in this sector that have been oversold and are being tipped to do well. Another remains one to avoid, writes Graeme Evans.
AstraZeneca and Novo Nordisk are the leading picks and GSK is still one to avoid after a City bank revealed its 2025 forecasts for an “inexpensive” European pharma sector.
Bank of America said the industry’s fundamentals remain strong, with the European majors set to deliver another year of market-beating earnings growth in the region of 14%.
However, this has been offset by stock-specific issues and the potential for uncertainty over healthcare policy in the sector’s single largest and most profitable market of the US.
As a result, European pharma trades on 12 times forecast 2026 earnings. That’s a slim 3% premium to the wider market, whereas the long-term average is 12%.
The bank believes the weakness since September has been overdone and that valuations are too focused on risks rather than growth and the potential of pipelines. Its target multiple of 16 times implies a 30% total return potential if overhangs are removed.
Despite its multiple of seven times 2026 earnings making GSK
GSK
0.34%
one of the lowest-rated stocks in the sector, the bank continues to have an Underperform recommendation.
This reflects headwinds for vaccines Arexvy and Shingrix, as well as GSK having the worst post-2026 growth outlook in the sector due to the loss of exclusivity on key products.
The shares are down 9% this year, despite the company recently ending two years of uncertainty by setting aside $2.2 billion to settle 93% of Zantac litigation claims.
Third-quarter results in late October showed vaccine sales fell 15%, impacted by a tough comparative and the prioritisation of Covid vaccinations in the United States.
Shingles product Shingrix dropped 7% as lower demand in the US more than offset stronger international uptake. And the respiratory syncytial virus vaccine Arexvy also missed City targets by some distance, with a 72% decline to £188 million.
The pressure on GSK shares and other European pharma stocks continued at the end of November after president-elect Donald Trump nominated vaccine-sceptic Robert F. Kennedy Jr as health secretary.
While this brings the prospect of four years of uncertainty over healthcare policy, Bank of America believes this is already reflected in the sector's discounted P/E multiple. |
Five shares to watch for 2025
GSK
GSK logo
Quality and value
Pharmaceutical company GSK is becoming a dependable name for raising and meeting guidance. That may not continue forever, but even after coming up against some headwinds in the vaccines franchise, it’s on track to meet its twice upgraded guidance for 2024.
The financial progress is underpinned by excellence in research and development that’s seen 11 positive late stage clinical updates from recent results, and is expected to yield five major product approvals next year. Beyond vaccines, the group also has a strong presence in HIV treatments, which make up about 20% of total revenues. Its newer treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments, and sales growth in the category remains healthy. The smaller oncology division is growing very rapidly, with promising growth drivers in both existing treatments and the development pipeline.
However, the pharmaceutical industry comes with high exposure to changes in the political landscape as well as the inherent risk of failed clinical trials so investors should be prepared for disappointments.
More recently, the valuation’s been held back by litigation relating to the heartburn drug Zantac. We believe developments on that front have materially reduced a key risk. But that’s not been enough to offset investor concerns around the US performance of two key products, Arexvy and Shingrix.
Given the impact on next year’s forecasts have been fairly limited, the continued pressure on the valuation looks to be overdone, which could offer an attractive entry point to an impressive business. And on the plus side, valuation weakness has helped push the forward prospective dividend yield to 4.9%. As ever, no returns are guaranteed. |
cumnor as a new buyer of GSK stock the past is irrelevant to me. All that matters is the price today and the potential going forward. |
Meant the latter.. |
But the problem was that 80p was based on unsustainable borrowing and the plan was to a) cheekily offload a lot of debt on Haleon and b) grow the pipeline and sales (and by extension the dividend) by focusing on vaccines and a few therapeutic pharma areas. But, of course, it's hard to take a divi reduction when valuation has also collapsed. But how much of the former is actually poor sentinent rather than a true reflection of how the company is faring at this point? |
No longer acceptable 60p divi-should be 80p 2025-to attract any institutional interest in present environment. Emma messed up and no mention of progressive dividend policy recent update. Investors have no confidence in her ability, and so they just unload shares at every opportunity. |
Share price back down and almost 2% in USA |
5 shares for 2025
Quality and value
Pharmaceutical company GSK is becoming a dependable name for raising and meeting guidance. That may not continue forever, but even after coming up against some headwinds in the vaccines franchise, it’s on track to meet its twice upgraded guidance for 2024.
The financial progress is underpinned by excellence in research and development that’s seen 11 positive late stage clinical updates from recent results, and is expected to yield five major product approvals next year. Beyond vaccines, the group also has a strong presence in HIV treatments, which make up about 20% of total revenues. Its newer treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments, and sales growth in the category remains healthy. The smaller oncology division is growing very rapidly, with promising growth drivers in both existing treatments and the development pipeline.
However, the pharmaceutical industry comes with high exposure to changes in the political landscape as well as the inherent risk of failed clinical trials so investors should be prepared for disappointments.
More recently, the valuation’s been held back by litigation relating to the heartburn drug Zantac. We believe developments on that front have materially reduced a key risk. But that’s not been enough to offset investor concerns around the US performance of two key products, Arexvy and Shingrix.
Given the impact on next year’s forecasts have been fairly limited, the continued pressure on the valuation looks to be overdone, which could offer an attractive entry point to an impressive business. And on the plus side, valuation weakness has helped push the forward prospective dividend yield to 4.9%. As ever, no returns are guaranteed. |
Look at the way share price goes down a total disgrace . |
I doubt it means anything but anyone else notice the last year's chart looks like a massive head and shoulders? :0 |
1300 to nearly 1400 pence did not take too long here on the upward leg, hopefully we are back on the every 2 year cycle of rising towards 1800 again now.. :o) |
GSK plc announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for review. A decision from the regulatory body is expected on May 7, 2025. |
Blenrep could be worth more than £3billion in annual sales for GSK if it comes to market. |
 LONDON - GSK plc announced significant overall survival (OS) results from the DREAMM-7 trial, which showed a 42% reduction in the risk of death for patients treated with Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd), compared to a daratumumab-based regimen. The data, presented at the 66th American Society of Hematology (ASH) Annual Meeting, could potentially reshape the standard of care for multiple myeloma patients at or after first relapse.
The trial, which included 494 participants, revealed that the three-year OS rate was 74% in the BVd arm versus 60% in the daratumumab combination arm, with the survival benefit observed as early as four months. Although the median overall survival was not reached in either study arm, projections suggest a median OS of 84 months for BVd, compared to 51 months for the daratumumab combination.
In addition to the OS benefit, the Blenrep combination demonstrated a greater than 2.5-fold improvement in minimal residual disease (MRD) negativity rate, indicating no detectable cancer cells, compared to the daratumumab combination. The results also included improvements in other key secondary efficacy endpoints, such as duration of response (DOR) and progression-free survival 2 (PFS 2), suggesting deeper and more durable responses with BVd.
The safety profile of the Blenrep combination was consistent with previous analyses, with manageable and resolvable eye-related side effects, leading to a low treatment discontinuation rate. The trial's findings build upon earlier results from the DREAMM-7 and DREAMM-8 trials, which demonstrated improvements in progression-free survival.
Regulatory reviews of Blenrep combinations based on the DREAMM-7 and DREAMM-8 trials are underway in several major markets, including the US, European Union, Japan, China, United Kingdom (TADAWUL:4280), Canada, and Switzerland. The DREAMM clinical development program continues to assess the potential of belantamab mafodotin in various treatment combinations and settings. |
4% up in the US |
Think they have an agenda? |
Was there any point? :/ |
BofA Global Research cuts price objective to 1415p from 1425p |
LONDON - GSK plc (LSE/NYSE: GSK) announced Monday that the National Medical (TASE:PMCN) Products Administration (NMPA) of China has accepted the new drug application for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone for priority review. This treatment is aimed at patients with relapsed or refractory multiple myeloma, a condition which has seen rising cases in China.
The submission is supported by phase III DREAMM-7 trial results, which demonstrated a statistically significant improvement in overall survival for patients treated with the Blenrep combination compared to the current standard of care. The trial met its primary endpoint by showing a clinically meaningful improvement in progression-free survival (PFS).
This marks the seventh major regulatory filing acceptance in 2024 for belantamab mafodotin combinations based on the DREAMM-7 and DREAMM-8 trials, with previous acceptances for review in the US, European Union, Japan, United Kingdom (TADAWUL:4280), Canada, and Switzerland.
Multiple myeloma is the third most common blood cancer globally, and while treatable, is not considered curable. In China, the disease has doubled in incidence and mortality has increased over the last thirty years. The Blenrep combination could potentially offer a new treatment option for patients at first relapse, addressing a significant unmet medical need. |
Muna Therapeutics has entered a research alliance with GSK to expedite Alzheimer's disease treatments by discovering and validating new drug targets.
The partnership is set to leverage Muna's MiND-MAP platform's spatial transcriptomics to analyse brain samples from groups including Alzheimer's patients and cognitively resilient individuals.
It also utilises Muna's expertise in mapping the response of the brain to pathological protein aggregates.
Muna will receive €33.5m ($35.2m) in an upfront payment from GSK, which also includes potential milestone payments of €140m ($147.1m) per target, plus tiered royalties on the net sales of any resulting products.
By examining postmortem human brain samples, the companies will identify potential new drug targets, which will be validated using Muna's humanised cell and animal models suite with additional insights provided by patient tissue and biofluid samples.
Muna will be responsible for leading the target identification and validation, while GSK will take the reins on drug development, overseeing preclinical activities, clinical development, manufacturing and commercialisation. |
HL has included GSK as one of 5 shares to watch in 2025
Pharmaceutical company GSK is becoming a dependable name for raising and meeting guidance. That may not continue forever, but even after coming up against some headwinds in the vaccines franchise, it’s on track to meet its twice upgraded guidance for 2024.
The financial progress is underpinned by excellence in research and development that’s seen 11 positive late stage clinical updates from recent results, and is expected to yield five major product approvals next year. Beyond vaccines, the group also has a strong presence in HIV treatments, which make up about 20% of total revenues. Its newer treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments, and sales growth in the category remains healthy. The smaller oncology division is growing very rapidly, with promising growth drivers in both existing treatments and the development pipeline.
However, the pharmaceutical industry comes with high exposure to changes in the political landscape as well as the inherent risk of failed clinical trials so investors should be prepared for disappointments.
More recently, the valuation’s been held back by litigation relating to the heartburn drug Zantac. We believe developments on that front have materially reduced a key risk. But that’s not been enough to offset investor concerns around the US performance of two key products, Arexvy and Shingrix.
Given the impact on next year’s forecasts have been fairly limited, the continued pressure on the valuation looks to be overdone, which could offer an attractive entry point to an impressive business. And on the plus side, valuation weakness has helped push the forward prospective dividend yield to 4.9%. As ever, no returns are guaranteed. |
I never automatically reinvest divis into the issuing share because it may not be the optimum choice in a diversified income port like mine. When I do have surplus divi cash to reinvest, all the shares in the port have to compete for it or perhaps a new holding. GSK has not been the most attractive choice for some years... |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
